Skip to main content
Shionogi & Co.,Ltd. logo

Shionogi & Co.,Ltd. — Investor Relations & Filings

Ticker · 4507 ISIN · JP3347200002 LEI · 35380049VXDTHZI3DY35 T Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country JP Japan
Listing T 4507

About Shionogi & Co.,Ltd.

https://www.shionogi.com/global/en/

Shionogi & Co., Ltd. is a drug discovery-based pharmaceutical company that researches, develops, manufactures, and markets a portfolio of prescription drugs, over-the-counter (OTC) products, and diagnostic reagents. The company prioritizes addressing unmet medical needs, with a significant focus on infectious diseases, including antibiotics, HIV, influenza, and COVID-19. A key strategic area is the development of solutions to combat antimicrobial resistance (AMR). Historically, the company is known for the development of Crestor, a widely used statin. Shionogi aims to provide innovative products and services to improve global health outcomes.

Recent filings

Filing Released Lang Actions
抗新型コロナウイルス（SARS-CoV-2）薬 エンシトレルビル フマル酸の COVID-19 曝露後発症予防における米国FDAの承認について
Regulatory Filings Classification · 60% confidence The document is a corporate press release announcing FDA approval for a COVID-19 prophylactic drug. It does not contain financial statements, earnings results, board changes, or meeting materials. It is a general regulatory announcement (drug approval), fitting the fallback category for miscellaneous regulatory filings. Therefore, it is classified as Regulatory Filings (RNS).
2026-06-01 Japanese
オピオイド誘発性便秘症治療薬ナルデメジンの中国における新薬承認取得について
Regulatory Filings Classification · 60% confidence The document is a corporate press release announcing regulatory approval of a pharmaceutical product in China. It contains no financial statements, management changes, earnings data, or formal voting results. It is not an investor presentation or financial report, but rather a general company announcement. This does not fit any specific filing category other than the general catch-all for miscellaneous regulatory announcements. Therefore it is classified as a Regulatory Filing (RNS).
2026-05-29 Japanese
訂正臨時報告書
M&A Activity Classification · 94% confidence The document is a 臨時報告書 (extraordinary/timely report) filed under the Financial Instruments and Exchange Act disclosing the absorption‐type merger of the wholly owned subsidiary Torii Pharmaceuticals by Shionogi & Co. It provides detailed merger terms, schedules, financial and corporate information about the merging parties. This is clearly an M&A announcement and fits the definition of M&A Activity (Code: TAR).
2026-04-27 Japanese
当社の完全子会社である鳥居薬品株式会社の吸収合併（簡易合併・略式合併）に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
2026年3月期 配当予想の修正（増配）に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 161
2025-11-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.